ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2011
A nationwide study of Campylobacter jejuni and Campylobacter coli bacteremia in Finland over a 10-year period, 1998-2007, with special reference to clinical characteristics and antimicrobial susceptibility.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Clinical Outcomes ofPathogens (Basel, Switzerland) · 2026Pooled it
- Effects of Inappropriate Administration of Empirical Antibiotics on Mortality in Adults With Bacteraemia: Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Campylobacter jejuni as a Rare Pathogen in CIED Pocket Infections: A Case Report and Literature Review.The American journal of case reports · 2026Review
- Article
- The clinical characteristics and outcomes of Campylobacter spp. bloodstream infection: A systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- [Bacteremia secondary toRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Article
- Article
- Differences in the Clinical Characteristics of Campylobacteriosis between Immunocompromised and Immunocompetent Patients: a Single-Center Retrospective Cohort Study in Japan.Open forum infectious diseases · 2025Article
- Evaluation of a rapid fluorescence immunoassay for detecting Campylobacter antigens in stool samples.Gut pathogens · 2025Article
- Spinal Epidural Abscess Caused by Campylobacter jejuni Without Gastrointestinal Symptoms.Cureus · 2024Article
- Article
- Campylobacter gastroenteritis and bacteremia in an asplenic patient with a recent history ofIDCases · 2024Article
- Vertebral osteomyelitis withJournal of bone and joint infection · 2024Article
- Vertebral osteomyelitis caused by Campylobacter jejuni in an immunocompetent patient.Gut pathogens · 2023Article
- Epidemiology and Antimicrobial Resistance ofOpen forum infectious diseases · 2023Article
- Multicenter Retrospective Study of Vascular Infections and Endocarditis Caused by Campylobacter spp., France.Emerging infectious diseases · 2023Review
- Clinical characteristics of Campylobacter bacteremia: a multicenter retrospective study.Scientific reports · 2023Article
- Campylobacter jejuni Bacteremia in the Term Infant A Rare Cause of Neonatal Hematochezia.The Pediatric infectious disease journal · 2022Article
- Campylobacter coli infection causes spinal epidural abscess with Guillain-Barré syndrome: a case report.BMC neurology · 2022Article
- LateJPRAS open · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCampylobacter bacteremia is an uncommon condition, usually diagnosed in elderly and immunocompromised patients.
methodsBlood culture isolates and clinical information were collected for patients with diagnoses of Campylobacter jejuni or Campylobacter coli bacteremia in Finland from 1998 through 2007. Bacterial species were identified by means of polymerase chain reaction analysis, and minimal inhibitory concentrations for ciprofloxacin, clindamycin, doxycycline, erythromycin, gentamicin, meropenem, and metronidazole were determined with an agar dilution method. Medical records and mortality data within 1 year after the bacteremic episode were reviewed.
resultsThe study included 76 patients (median age, 46 years), for whom bacterial isolates (C. jejuni in 73, C. coli in 3) and clinical information were available. Most patients (70%) had no significant underlying diseases. The majority (82%) of the isolates were susceptible for all antimicrobial agents tested. However, antimicrobial therapy seemed to have only a limited effect, because no differences could be detected between patients with appropriate empirical antimicrobial treatment and those with delayed appropriate, inappropriate, or no antimicrobial therapy, either in the duration of hospitalization (median, 4 days for both groups) or in attributable mortality. The outcome of the infection was severe in 4 patients infected with C. jejuni; 2 died within 30 days, spondylodiscitis developed in 1, and Guillain-Barré syndrome developed in 1.
conclusionsC. jejuni and C. coli bacteremia occurred mainly in moderately young individuals without severe underlying diseases. The bacterial isolates were predominantly susceptible to antimicrobial agents, and the outcome of the disease was typically good, regardless of appropriate or inappropriate antimicrobial treatment given in the hospital.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.